Semaglutide Trial Protocol Aims to Improve Metabolic Abnormalities and Fertility in Obese Infertile Women with PCOS
Background
Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder affecting women of reproductive age, characterized by hormonal imbalances, insulin resistance, obesity, and infertility. Current treatments often address symptoms individually, but a significant gap remains in comprehensively managing both metabolic dysfunction and reproductive challenges. Obesity exacerbates PCOS symptoms and complicates fertility treatments. GLP-1 receptor agonists like semaglutide have shown promise in weight management and improving metabolic parameters, making them a compelling candidate for addressing the multifaceted pathology of obese infertile PCOS patients.
Study Design
This prospective, randomized, open, and controlled study protocol plans to recruit 75 obese infertile PCOS patients of childbearing age. Participants will be randomized into three groups: metformin, semaglutide, or metformin+semaglutide, all alongside a calorie-restricted diet and physical exercise. Treatment will last 12 weeks. Following treatment, drugs will be stopped for at least 8 weeks before initiating ovulation induction or ovulation induction combined with artificial insemination. Subjects will be followed for 24 weeks to assess pregnancy outcomes. The primary endpoint is the percentage of weight loss at 12 weeks. Secondary endpoints include HOMA-IR and androgen levels at 12 weeks, ovulation rate, clinical pregnancy rate, cumulative pregnancy rate, and quality of life scores at 12 weeks.
Results
This abstract describes a study protocol, and therefore, no results or findings are available yet. The study is designed to measure specific endpoints after 12 weeks of treatment and 24 weeks of follow-up. The primary outcome will be the percentage of weight loss, with secondary outcomes including improvements in HOMA-IR and androgen levels, as well as ovulation and pregnancy rates. Data on depression, anxiety, diet, and quality of life scores will also be collected. The trial aims to provide concrete data on semaglutide's impact in this specific patient population.
Key Findings
- This is a study protocol; no findings are available yet.
Why It Matters
If successful, this protocol could establish semaglutide as a valuable therapeutic option for obese infertile women with PCOS, potentially improving both metabolic health and reproductive outcomes. Current approaches often require multiple interventions; a single agent or combination therapy that addresses weight, insulin resistance, and androgen excess could simplify treatment paradigms. The focus on fertility endpoints, including ovulation and pregnancy rates, directly addresses a critical unmet need. This study's findings could inform future clinical guidelines, potentially leading to new preconception care strategies for women struggling with PCOS-related infertility. While a usable protocol is still some time away, positive results would significantly advance the clinical translation of GLP-1RAs in this context.
semaglutide
pcos
infertility
obesity
metabolic-syndrome
rct